Institute of Cancer Research
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Institute of Cancer Research
A mix of mega-rounds and smaller seed financings show investment happening at both ends of the venture capital spectrum. In public company financings, Gilead prices $2bn note offering, Biogen secures $1.5bn for Reata deal, Inhibrx completes a $200m PIPE and the IPO market shows new signs of life.
MD Anderson and the US National Cancer Institute lead the way with a series of recent alliances, highlighted in this special edition of Tech Transfer Roundup focused on oncology.
Private Company Edition: Arvelle, insitro, AbCellera and the University of Michigan have something in common – they each attracted more than $100m in venture capital investment.
In a busy week, Carrick Therapeutics has added to its oncology pipeline, as well as bringing in Celgene deal maker George Golumbeski.
- Academic and Research Institutions
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.